$SHPH
Shuttle Pharmaceuticals Holdings, Inc.

2024 Q3 Form 10-Q Financial Statement

#000149315224034902 Filed on September 04, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $1.401M $645.7K
YoY Change 22.82% -30.82%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.052M $1.483M
YoY Change 90.82% 1.16%
Operating Profit -$3.052M -$1.483M
YoY Change 90.82% 1.16%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$732.5K -$548.6K
YoY Change 278.35% -23.67%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$3.784M -$2.031M
YoY Change 111.08% -7.01%
Net Earnings / Revenue
Basic Earnings Per Share -$1.59 -$0.96
Diluted Earnings Per Share -$1.59 -$0.96
COMMON SHARES
Basic Shares Outstanding 2.227M shares 16.79M shares
Diluted Shares Outstanding 2.384M shares 2.105M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $156.7K $695.6K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $103.0K $139.5K
Receivables
Other Receivables
Total Short-Term Assets $361.4K $2.485M
YoY Change -94.83% -70.56%
LONG-TERM ASSETS
Property, Plant & Equipment $21.16K $21.95K
YoY Change -21.07% 128.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $312.2K $327.7K
YoY Change -17.88% -16.79%
TOTAL ASSETS
Total Short-Term Assets $361.4K $2.485M
Total Long-Term Assets $312.2K $327.7K
Total Assets $673.6K $2.813M
YoY Change -90.87% -68.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.659M $1.385M
YoY Change 104.73% 180.47%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.659M $1.385M
Total Long-Term Liabilities
Total Liabilities $1.989M $2.012M
YoY Change 12.62% 5.79%
SHAREHOLDERS EQUITY
Retained Earnings -$32.98M -$29.20M
YoY Change 138.17% 142.2%
Common Stock $29.00 $21.00
YoY Change -81.88% -86.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.315M $801.4K
YoY Change
Total Liabilities & Shareholders Equity $673.6K $2.813M
YoY Change -90.87% -68.17%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$3.784M -$2.031M
YoY Change 111.08% -7.01%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Operating Expenses
OperatingExpenses
2867481 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1482634 usd
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
SHPH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2226951 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
695594 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
139518 usd
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1642995 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2887215 usd
CY2024Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
7226 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29195550 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
801434 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001757499
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
usd
CY2024Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q2 us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001757499
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
usd
CY2024Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q2 us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
CY2024Q2 SHPH Finance Fee
FinanceFee
usd
SHPH Finance Fee
FinanceFee
usd
CY2024Q2 SHPH Loss On Settlement Of Convertible Debt
LossOnSettlementOfConvertibleDebt
usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
SHPH Increase Decrease In Accrued Interest Payable Related Parties
IncreaseDecreaseInAccruedInterestPayableRelatedParties
usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
CY2023Q2 SHPH Finance Fee
FinanceFee
usd
SHPH Finance Fee
FinanceFee
usd
CY2024Q2 SHPH Loss On Settlement Of Convertible Debt
LossOnSettlementOfConvertibleDebt
usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
SHPH Increase Decrease In Accrued Interest Payable Related Parties
IncreaseDecreaseInAccruedInterestPayableRelatedParties
usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
SHPH Warrants Issued For Financing Fees
WarrantsIssuedForFinancingFees
usd
SHPH Initial Recognition Of Right Of Use Asset And Liability
InitialRecognitionOfRightOfUseAssetAndLiability
usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
SHPH Initial Recognition Of Right Of Use Asset And Liability
InitialRecognitionOfRightOfUseAssetAndLiability
usd
us-gaap Revenues
Revenues
usd
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
usd
us-gaap Variable Lease Cost
VariableLeaseCost
usd
CY2024Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
CY2023Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
us-gaap Revenues
Revenues
usd
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
usd
us-gaap Variable Lease Cost
VariableLeaseCost
usd
CY2024Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
CY2023Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity File Number
EntityFileNumber
001-41488
CY2024Q2 us-gaap Assets Current
AssetsCurrent
2485333 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
5593005 usd
dei Entity Registrant Name
EntityRegistrantName
SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-5089826
dei Entity Address Address Line1
EntityAddressAddressLine1
401 Professional Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 260
dei Entity Address City Or Town
EntityAddressCityOrTown
Gaithersburg
dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20879
dei City Area Code
CityAreaCode
(240)
dei Local Phone Number
LocalPhoneNumber
403-4212
CY2024Q2 us-gaap Assets Current
AssetsCurrent
2485333 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
5593005 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21953 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24827 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
305712 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
333904 usd
CY2024Q2 us-gaap Assets
Assets
2812998 usd
CY2023Q4 us-gaap Assets
Assets
5951736 usd
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
130898 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
110453 usd
CY2024Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
826235 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
595999 usd
CY2024Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
504 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
62092 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
52479 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1384620 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1042237 usd
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
135089 usd
CY2024Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
359919 usd
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
414512 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
267025 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
304127 usd
CY2024Q2 us-gaap Liabilities
Liabilities
2011564 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1895965 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
1000
CY2023Q4 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
1000
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2106233 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2106233 shares
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21953 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24827 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
305712 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
333904 usd
CY2024Q2 us-gaap Assets
Assets
2812998 usd
CY2023Q4 us-gaap Assets
Assets
5951736 usd
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
130898 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
110453 usd
CY2024Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
826235 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
595999 usd
CY2024Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
504 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
62092 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
52479 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1384620 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1042237 usd
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
135089 usd
CY2024Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
359919 usd
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
414512 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
267025 usd
CY2024Q2 us-gaap Liabilities
Liabilities
2011564 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1895965 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
1000
CY2023Q4 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
1000
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2106233 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2106233 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2008689 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
21 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
20 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
29489055 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25433304 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4055771 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5951736 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
645719 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
839665 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1231823 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
310038 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
209279 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
634647 usd
CY2024Q2 us-gaap Legal Fees
LegalFees
526877 usd
CY2023Q2 us-gaap Legal Fees
LegalFees
416688 usd
us-gaap Legal Fees
LegalFees
1001011 usd
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2008689 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2008689 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
20 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
29996963 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25433304 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4055771 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2812998 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5951736 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
645719 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
839665 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1231823 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1761466 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
310038 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
209279 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
634647 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
464633 usd
CY2024Q2 us-gaap Legal Fees
LegalFees
526877 usd
CY2023Q2 us-gaap Legal Fees
LegalFees
416688 usd
us-gaap Legal Fees
LegalFees
1001011 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
1482634 usd
us-gaap Operating Expenses
OperatingExpenses
3010411 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1465632 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3010411 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
14158 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
19267 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
35611 usd
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
434275 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
54089 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1675275 usd
CY2024Q2 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
39683 usd
CY2023Q2 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
1744 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
43720 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
1744 usd
CY2024Q2 us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-27964 usd
CY2023Q2 us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-26534 usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-28670 usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
11528 usd
CY2023Q2 SHPH Loss On Settlement Of Convertible Debt
LossOnSettlementOfConvertibleDebt
415553 usd
SHPH Loss On Settlement Of Convertible Debt
LossOnSettlementOfConvertibleDebt
71315 usd
SHPH Loss On Settlement Of Convertible Debt
LossOnSettlementOfConvertibleDebt
433807 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-548581 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-718740 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-894765 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-149057 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2031215 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2184372 usd
us-gaap Net Income Loss
NetIncomeLoss
-3159468 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2104933 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2104933 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1780171 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1780171 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2090890 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2090890 shares
us-gaap Legal Fees
LegalFees
784312 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
1482634 usd
us-gaap Operating Expenses
OperatingExpenses
3010411 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1465632 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2867481 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3010411 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
14158 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
19267 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
35611 usd
CY2024Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-143773 usd
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
434275 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
54089 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1675275 usd
CY2024Q2 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
39683 usd
CY2023Q2 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
1744 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
43720 usd
CY2023Q2 us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-26534 usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-28670 usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
11528 usd
SHPH Loss On Settlement Of Convertible Debt
LossOnSettlementOfConvertibleDebt
71315 usd
SHPH Loss On Settlement Of Convertible Debt
LossOnSettlementOfConvertibleDebt
433807 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-718740 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-894765 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-149057 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2031215 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2184372 usd
us-gaap Net Income Loss
NetIncomeLoss
-3762246 usd
us-gaap Net Income Loss
NetIncomeLoss
-3159468 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2104933 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2104933 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1780171 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1780171 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2090890 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2090890 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1742520 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1742520 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.81
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4055771 usd
CY2024Q1 SHPH Stock Issued During Period Value Conversion Of Accrued Interest And Principal
StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
325298 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
111449 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1731031 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2761487 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
71162 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2031215 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
801434 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7677869 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
1482634 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1465632 usd
us-gaap Operating Expenses
OperatingExpenses
3010411 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1465632 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3010411 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
14158 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
19267 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
35611 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
35955 usd
SHPH Finance Fee
FinanceFee
104245 usd
CY2024Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-143773 usd
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
434275 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
54089 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1675275 usd
CY2024Q2 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
39683 usd
CY2023Q2 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
1744 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
43720 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
1744 usd
CY2023Q2 us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-26534 usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-28670 usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
11528 usd
SHPH Loss On Settlement Of Convertible Debt
LossOnSettlementOfConvertibleDebt
71315 usd
SHPH Loss On Settlement Of Convertible Debt
LossOnSettlementOfConvertibleDebt
433807 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-548581 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-718740 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-894765 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-149057 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2031215 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2184372 usd
us-gaap Net Income Loss
NetIncomeLoss
-3762246 usd
us-gaap Net Income Loss
NetIncomeLoss
-3159468 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2104933 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2104933 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1780171 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1780171 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2090890 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2090890 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1742520 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1742520 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.81
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4055771 usd
CY2024Q1 SHPH Stock Issued During Period Value Conversion Of Accrued Interest And Principal
StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
325298 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
111449 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1731031 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2761487 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
71162 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2031215 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1742520 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1742520 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.81
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4055771 usd
CY2024Q1 SHPH Stock Issued During Period Value Conversion Of Accrued Interest And Principal
StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
325298 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
111449 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1731031 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2761487 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
71162 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2031215 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
801434 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7677869 usd
CY2023Q1 SHPH Warrants Issuance Fees
WarrantsIssuanceFees
8727 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
90816 usd
CY2023Q1 SHPH Stock Issued During Period Value Conversion Of Accrued Interest And Principal
StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
104547 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8333 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-975097 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
6906468 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
6906468 usd
CY2023Q2 SHPH Stock Issued During Period Value Conversion Of Accrued Interest And Principal
StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
2163992 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
49522 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2184372 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6935610 usd
us-gaap Net Income Loss
NetIncomeLoss
-3762246 usd
us-gaap Net Income Loss
NetIncomeLoss
-3159468 usd
us-gaap Depreciation
Depreciation
2874 usd
us-gaap Depreciation
Depreciation
2970 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
54089 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1675275 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
832014 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1116422 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
43720 usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-28670 usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
11528 usd
SHPH Accrued Interest Settled With Common Stock
AccruedInterestSettledWithCommonStock
18783 usd
SHPH Accrued Interest Settled With Common Stock
AccruedInterestSettledWithCommonStock
240831 usd
SHPH Loss On Settlement Of Convertible Debt
LossOnSettlementOfConvertibleDebt
71315 usd
SHPH Loss On Settlement Of Convertible Debt
LossOnSettlementOfConvertibleDebt
433807 usd
us-gaap Share Based Compensation
ShareBasedCompensation
182611 usd
us-gaap Share Based Compensation
ShareBasedCompensation
57855 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-7675 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
6950 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
25045 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-82199 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
82031 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-28004 usd
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-446 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
801434 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7677869 usd
CY2023Q1 SHPH Warrants Issuance Fees
WarrantsIssuanceFees
8727 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
90816 usd
CY2023Q1 SHPH Stock Issued During Period Value Conversion Of Accrued Interest And Principal
StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
104547 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8333 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-975097 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
6906468 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
6906468 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
49522 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2184372 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6935610 usd
us-gaap Net Income Loss
NetIncomeLoss
-3762246 usd
us-gaap Net Income Loss
NetIncomeLoss
-3159468 usd
us-gaap Depreciation
Depreciation
2970 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
54089 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1675275 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
832014 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1116422 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
43720 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
1744 usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-28670 usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
11528 usd
SHPH Accrued Interest Settled With Common Stock
AccruedInterestSettledWithCommonStock
18783 usd
SHPH Accrued Interest Settled With Common Stock
AccruedInterestSettledWithCommonStock
240831 usd
SHPH Loss On Settlement Of Convertible Debt
LossOnSettlementOfConvertibleDebt
71315 usd
SHPH Loss On Settlement Of Convertible Debt
LossOnSettlementOfConvertibleDebt
433807 usd
us-gaap Share Based Compensation
ShareBasedCompensation
182611 usd
us-gaap Share Based Compensation
ShareBasedCompensation
57855 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-7675 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
6950 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
25045 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-82199 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
82031 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-28004 usd
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-446 usd
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-12500 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
20445 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
75511 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
703 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-30 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2638425 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
35982 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2970905 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1295252 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
80000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1259270 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2890905 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
685473 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3935000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
345000 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
501667 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-501667 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1880822 usd
CY2023Q1 SHPH Warrants Issuance Fees
WarrantsIssuanceFees
8727 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
90816 usd
CY2023Q1 SHPH Stock Issued During Period Value Conversion Of Accrued Interest And Principal
StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
104547 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8333 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-975097 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
6906468 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
6906468 usd
CY2023Q2 SHPH Stock Issued During Period Value Conversion Of Accrued Interest And Principal
StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
2163992 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
49522 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2184372 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6935610 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6935610 usd
us-gaap Net Income Loss
NetIncomeLoss
-3762246 usd
us-gaap Net Income Loss
NetIncomeLoss
-3159468 usd
us-gaap Depreciation
Depreciation
2874 usd
us-gaap Depreciation
Depreciation
2970 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
54089 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
832014 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1116422 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
43720 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
1744 usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-28670 usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
11528 usd
SHPH Accrued Interest Settled With Common Stock
AccruedInterestSettledWithCommonStock
18783 usd
SHPH Accrued Interest Settled With Common Stock
AccruedInterestSettledWithCommonStock
240831 usd
SHPH Loss On Settlement Of Convertible Debt
LossOnSettlementOfConvertibleDebt
71315 usd
SHPH Loss On Settlement Of Convertible Debt
LossOnSettlementOfConvertibleDebt
433807 usd
us-gaap Share Based Compensation
ShareBasedCompensation
182611 usd
us-gaap Share Based Compensation
ShareBasedCompensation
57855 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-7675 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
6950 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
25045 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-82199 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
82031 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-28004 usd
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-446 usd
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-12500 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
20445 usd
SHPH Increase Decrease In Accrued Interest Payable Related Parties
IncreaseDecreaseInAccruedInterestPayableRelatedParties
-98135 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
703 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-30 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2638425 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2984039 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
35982 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2970905 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1295252 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1259270 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2890905 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
685473 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3935000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
345000 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
501667 usd
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-12500 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
20445 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
75511 usd
SHPH Increase Decrease In Accrued Interest Payable Related Parties
IncreaseDecreaseInAccruedInterestPayableRelatedParties
-98135 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
703 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-30 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2638425 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2984039 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
35982 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2970905 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1295252 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
80000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1259270 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2890905 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
685473 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3935000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
345000 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
501667 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-501667 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2904527 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1880822 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2970417 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2576416 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8417203 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
695594 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5446786 usd
us-gaap Interest Paid Net
InterestPaidNet
56958 usd
us-gaap Interest Paid Net
InterestPaidNet
102373 usd
SHPH Common Stock Issued For Settlement Of Debt
CommonStockIssuedForSettlementOfDebt
2268539 usd
SHPH Warrants Issuance Fees
WarrantsIssuanceFees
0 usd
SHPH Warrants Issuance Fees
WarrantsIssuanceFees
8727 usd
SHPH Warrants Issued For Financing Fees
WarrantsIssuedForFinancingFees
90816 usd
us-gaap Net Income Loss
NetIncomeLoss
-3800000 usd
SHPH Working Capital
WorkingCapital
1100000 usd
CY2024Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
600000 usd
CY2023Q1 us-gaap Partners Capital
PartnersCapital
4500000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-501667 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1880822 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2970417 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2576416 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8417203 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
695594 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5446786 usd
us-gaap Interest Paid Net
InterestPaidNet
56958 usd
SHPH Common Stock Issued For Settlement Of Debt
CommonStockIssuedForSettlementOfDebt
325298 usd
SHPH Common Stock Issued For Settlement Of Debt
CommonStockIssuedForSettlementOfDebt
2268539 usd
SHPH Warrants Issuance Fees
WarrantsIssuanceFees
0 usd
SHPH Warrants Issuance Fees
WarrantsIssuanceFees
8727 usd
SHPH Warrants Issued For Financing Fees
WarrantsIssuedForFinancingFees
90816 usd
SHPH Initial Recognition Of Right Of Use Asset And Liability
InitialRecognitionOfRightOfUseAssetAndLiability
365556 usd
us-gaap Net Income Loss
NetIncomeLoss
-3800000 usd
CY2024Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
600000 usd
CY2023Q1 us-gaap Partners Capital
PartnersCapital
4500000 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2106233 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2106233 shares
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zksTHwoVOVLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zty8POBdZ14f">Correction of an Immaterial Error in the Prior Period Financial Statements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the fourth quarter of 2023, the Company determined that the prior year consolidated financial statements had a misstatement caused by an immaterial classification error of certain research and development expenses in accordance with Accounting Standards Codification (“ASC”) 730. As a result, certain prior year amounts have been corrected for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99, “Materiality,” (ASC Topic 250, Accounting Changes and Error Corrections). Based on this assessment, the Company concluded that these error corrections in its unaudited condensed consolidated statements of operations are not material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had no impact on the unaudited condensed consolidated balance sheet, unaudited condensed consolidated statements of cash flows, or unaudited condensed consolidated statement of changes in stockholders’ equity, to these financial statements, or for any previously presented interim or annual financial statements. Further, the corrections did not result in a change in quarterly or year-to-date operating losses, basic or diluted earnings per share, or working capital. The quarterly correction required for the three and six months ended June 30, 2023 was $<span id="xdx_902_eus-gaap--GeneralAndAdministrativeExpense_c20230401__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zfwXh28jt8qd">93,708</span> and $<span id="xdx_907_eus-gaap--GeneralAndAdministrativeExpense_c20230101__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zG3rqon8xnki">182,715</span>, respectively. Accordingly, the Company corrected the previously reported immaterial error for the three and six months ended June 30, 2023 in this Quarterly Report on Form 10-Q.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zFGYTcvAYqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zUEa4AVq93g1" style="display: none">Schedule of the Error Correction</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20230101__20230630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z3Z7GTOKMz71" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20230101__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zlup5tiXDzn5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Correction</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20230101__20230630_zHG6NPgkwPuh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Corrected</p> <p style="margin-top: 0; margin-bottom: 0">June 30, 2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_zaZtpqWvJG87" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Research and development expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,944,181</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(182,715</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,761,466</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_zhmSXxZoGwc5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">281,918</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">182,715</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">464,633</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ProfitLoss_zShvxDCsAKYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,226,099</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0620">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,226,099</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_z68fXjAtDtY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2970417 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2576416 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8417203 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
695594 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5446786 usd
us-gaap Interest Paid Net
InterestPaidNet
56958 usd
us-gaap Interest Paid Net
InterestPaidNet
102373 usd
SHPH Warrants Issuance Fees
WarrantsIssuanceFees
0 usd
SHPH Warrants Issuance Fees
WarrantsIssuanceFees
8727 usd
SHPH Initial Recognition Of Right Of Use Asset And Liability
InitialRecognitionOfRightOfUseAssetAndLiability
365556 usd
us-gaap Net Income Loss
NetIncomeLoss
-3800000 usd
SHPH Working Capital
WorkingCapital
1100000 usd
CY2024Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
600000 usd
CY2023Q1 us-gaap Partners Capital
PartnersCapital
4500000 usd
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2106233 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2106233 shares
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zksTHwoVOVLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zty8POBdZ14f">Correction of an Immaterial Error in the Prior Period Financial Statements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the fourth quarter of 2023, the Company determined that the prior year consolidated financial statements had a misstatement caused by an immaterial classification error of certain research and development expenses in accordance with Accounting Standards Codification (“ASC”) 730. As a result, certain prior year amounts have been corrected for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99, “Materiality,” (ASC Topic 250, Accounting Changes and Error Corrections). Based on this assessment, the Company concluded that these error corrections in its unaudited condensed consolidated statements of operations are not material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had no impact on the unaudited condensed consolidated balance sheet, unaudited condensed consolidated statements of cash flows, or unaudited condensed consolidated statement of changes in stockholders’ equity, to these financial statements, or for any previously presented interim or annual financial statements. Further, the corrections did not result in a change in quarterly or year-to-date operating losses, basic or diluted earnings per share, or working capital. The quarterly correction required for the three and six months ended June 30, 2023 was $<span id="xdx_902_eus-gaap--GeneralAndAdministrativeExpense_c20230401__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zfwXh28jt8qd">93,708</span> and $<span id="xdx_907_eus-gaap--GeneralAndAdministrativeExpense_c20230101__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zG3rqon8xnki">182,715</span>, respectively. Accordingly, the Company corrected the previously reported immaterial error for the three and six months ended June 30, 2023 in this Quarterly Report on Form 10-Q.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zFGYTcvAYqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zUEa4AVq93g1" style="display: none">Schedule of the Error Correction</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20230101__20230630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z3Z7GTOKMz71" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20230101__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zlup5tiXDzn5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Correction</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20230101__20230630_zHG6NPgkwPuh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Corrected</p> <p style="margin-top: 0; margin-bottom: 0">June 30, 2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_zaZtpqWvJG87" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Research and development expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,944,181</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(182,715</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,761,466</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_zhmSXxZoGwc5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">281,918</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">182,715</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">464,633</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ProfitLoss_zShvxDCsAKYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,226,099</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0620">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,226,099</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_z68fXjAtDtY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1761466 usd
us-gaap Profit Loss
ProfitLoss
2226099 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2106233 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2106233 shares
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zksTHwoVOVLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zty8POBdZ14f">Correction of an Immaterial Error in the Prior Period Financial Statements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the fourth quarter of 2023, the Company determined that the prior year consolidated financial statements had a misstatement caused by an immaterial classification error of certain research and development expenses in accordance with Accounting Standards Codification (“ASC”) 730. As a result, certain prior year amounts have been corrected for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99, “Materiality,” (ASC Topic 250, Accounting Changes and Error Corrections). Based on this assessment, the Company concluded that these error corrections in its unaudited condensed consolidated statements of operations are not material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had no impact on the unaudited condensed consolidated balance sheet, unaudited condensed consolidated statements of cash flows, or unaudited condensed consolidated statement of changes in stockholders’ equity, to these financial statements, or for any previously presented interim or annual financial statements. Further, the corrections did not result in a change in quarterly or year-to-date operating losses, basic or diluted earnings per share, or working capital. The quarterly correction required for the three and six months ended June 30, 2023 was $<span id="xdx_902_eus-gaap--GeneralAndAdministrativeExpense_c20230401__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zfwXh28jt8qd">93,708</span> and $<span id="xdx_907_eus-gaap--GeneralAndAdministrativeExpense_c20230101__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zG3rqon8xnki">182,715</span>, respectively. Accordingly, the Company corrected the previously reported immaterial error for the three and six months ended June 30, 2023 in this Quarterly Report on Form 10-Q.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zFGYTcvAYqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zUEa4AVq93g1" style="display: none">Schedule of the Error Correction</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20230101__20230630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z3Z7GTOKMz71" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20230101__20230630__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zlup5tiXDzn5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Correction</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20230101__20230630_zHG6NPgkwPuh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Corrected</p> <p style="margin-top: 0; margin-bottom: 0">June 30, 2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_zaZtpqWvJG87" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Research and development expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,944,181</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(182,715</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,761,466</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_zhmSXxZoGwc5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">281,918</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">182,715</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">464,633</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ProfitLoss_zShvxDCsAKYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,226,099</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0620">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,226,099</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_z68fXjAtDtY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1761466 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
464633 usd
us-gaap Profit Loss
ProfitLoss
2226099 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84B_eus-gaap--UseOfEstimates_zDxj36Lv1u87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z3JEbn1v7fOi">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Significant estimates are contained in the accompanying unaudited condensed consolidated financial statements for the recognition of research and development expenses, valuation of warrants and valuation of bifurcated derivative liabilities and other financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1761466 usd
us-gaap Profit Loss
ProfitLoss
2226099 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84B_eus-gaap--UseOfEstimates_zDxj36Lv1u87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z3JEbn1v7fOi">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Significant estimates are contained in the accompanying unaudited condensed consolidated financial statements for the recognition of research and development expenses, valuation of warrants and valuation of bifurcated derivative liabilities and other financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Cash
Cash
645594 usd
CY2023Q4 us-gaap Cash
Cash
1550098 usd
CY2024Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
50000 usd
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
1026318 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
695594 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2576416 usd
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
400000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84B_eus-gaap--UseOfEstimates_zDxj36Lv1u87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z3JEbn1v7fOi">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Significant estimates are contained in the accompanying unaudited condensed consolidated financial statements for the recognition of research and development expenses, valuation of warrants and valuation of bifurcated derivative liabilities and other financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Cash
Cash
645594 usd
CY2023Q4 us-gaap Cash
Cash
1550098 usd
CY2024Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
50000 usd
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
1026318 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
695594 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2576416 usd
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
400000 usd
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1600000 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2900000 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
14158 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
19267 usd
CY2024Q2 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
39683 usd
CY2023Q2 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
1744 usd
CY2024Q2 us-gaap Cash
Cash
645594 usd
CY2023Q4 us-gaap Cash
Cash
1550098 usd
CY2024Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
50000 usd
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
1026318 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
695594 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2576416 usd
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
400000 usd
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1600000 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2900000 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
14158 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
19267 usd
CY2024Q2 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
39683 usd
CY2023Q2 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
1744 usd
CY2024Q2 us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-27964 usd
CY2023Q2 us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-26534 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
35611 usd
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
43720 usd
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
1744 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
28670 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
11528 usd
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1600000 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2900000 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
14158 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
19267 usd
CY2024Q2 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
39683 usd
CY2023Q2 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
1744 usd
CY2024Q2 us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-27964 usd
CY2023Q2 us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-26534 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
35611 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
35955 usd
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
43720 usd
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
1744 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
28670 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
11528 usd
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1642995 usd
CY2024Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
360423 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
2887215 usd
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
414512 usd
CY2024Q2 us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-27964 usd
CY2023Q2 us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-26534 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
35611 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
35955 usd
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
43720 usd
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
1744 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
28670 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
11528 usd
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1642995 usd
CY2024Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
360423 usd
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
414512 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
323583 shares
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1642995 usd
CY2024Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
360423 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
2887215 usd
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
414512 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
323583 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
349760 shares
us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
6480 usd
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-10-31
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
25193 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
42737 usd
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
9937 usd
us-gaap Variable Lease Cost
VariableLeaseCost
20377 usd
CY2024Q2 us-gaap Sublease Income
SubleaseIncome
2163 usd
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
2121 usd
us-gaap Sublease Income
SubleaseIncome
4326 usd
us-gaap Sublease Income
SubleaseIncome
4242 usd
CY2024Q2 us-gaap Lease Cost
LeaseCost
30721 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
23072 usd
us-gaap Lease Cost
LeaseCost
61945 usd
us-gaap Lease Cost
LeaseCost
38495 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
42771 usd
us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
6480 usd
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-10-31
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
22947 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
25193 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
42737 usd
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
9937 usd
us-gaap Variable Lease Cost
VariableLeaseCost
20377 usd
CY2024Q2 us-gaap Sublease Income
SubleaseIncome
2163 usd
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
2121 usd
CY2024Q2 us-gaap Lease Cost
LeaseCost
30721 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
23072 usd
us-gaap Lease Cost
LeaseCost
38495 usd
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
22707 usd
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
23331 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
45189 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
42771 usd
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y11M23D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1048 pure
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1046 pure
us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
6480 usd
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-10-31
us-gaap Operating Lease Cost
OperatingLeaseCost
45894 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
42737 usd
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
9937 usd
us-gaap Variable Lease Cost
VariableLeaseCost
20377 usd
CY2024Q2 us-gaap Sublease Income
SubleaseIncome
2163 usd
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
2121 usd
CY2024Q2 us-gaap Lease Cost
LeaseCost
30721 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
23072 usd
us-gaap Lease Cost
LeaseCost
61945 usd
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
22707 usd
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
23331 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
45189 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
42771 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
365556 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M4D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y11M23D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1048 pure
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1046 pure
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
94246 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
99986 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
68235 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M4D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y11M23D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1048 pure
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1046 pure
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
46313 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
94246 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
97074 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
99986 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
68235 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
405854 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
329117 usd
CY2024Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
10000000.0 usd
CY2024Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
386505 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
832014 usd
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
501667 usd
us-gaap Interest Paid Net
InterestPaidNet
56958 usd
us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
558628 usd
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
549125 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
1012177 usd
CY2024Q2 us-gaap Convertible Debt
ConvertibleDebt
1517989 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
691754 usd
CY2024Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
826235 usd
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
127260 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
18.80
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
46313 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
94246 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
97074 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
99986 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
68235 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
405854 usd
CY2024Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
386505 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
832014 usd
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
501667 usd
us-gaap Interest Paid Net
InterestPaidNet
56958 usd
us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
558628 usd
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
549125 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
1012177 usd
CY2024Q2 us-gaap Convertible Debt
ConvertibleDebt
1517989 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
691754 usd
CY2024Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
826235 usd
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
127260 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
18.80
CY2024Q2 SHPH Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue
0 usd
CY2024Q1 us-gaap Sale Of Stock Consideration Received Per Transaction
SaleOfStockConsiderationReceivedPerTransaction
2250000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
405854 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
76737 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
329117 usd
CY2024Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
10000000.0 usd
CY2024Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
386505 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
832014 usd
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
501667 usd
us-gaap Interest Paid Net
InterestPaidNet
56958 usd
us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
558628 usd
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
549125 usd
CY2024Q2 us-gaap Convertible Debt
ConvertibleDebt
1517989 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
691754 usd
CY2024Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
826235 usd
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
127260 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
18.80
CY2024Q2 SHPH Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue
0 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
(i) one share of the Company’s common stock, (ii) a warrant to purchase one share of the Company’s common stock exercisable at a purchase price of $18.80 per share, and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC will own a 22% interest in Diagnostics.
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4500000 usd
CY2024Q1 us-gaap Sale Of Stock Consideration Received Per Transaction
SaleOfStockConsiderationReceivedPerTransaction
2250000 usd
us-gaap Direct Operating Costs
DirectOperatingCosts
142000 usd
CY2024Q2 SHPH Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue
0 usd
CY2024Q1 us-gaap Sale Of Stock Consideration Received Per Transaction
SaleOfStockConsiderationReceivedPerTransaction
2250000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
(i) one share of the Company’s common stock, (ii) a warrant to purchase one share of the Company’s common stock exercisable at a purchase price of $18.80 per share, and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC will own a 22% interest in Diagnostics.
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4500000 usd
CY2024Q1 us-gaap Sale Of Stock Consideration Received Per Transaction
SaleOfStockConsiderationReceivedPerTransaction
2250000 usd
us-gaap Direct Operating Costs
DirectOperatingCosts
142000 usd
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
127260 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
18.80
CY2023Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1189000 usd
CY2024Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
359919 usd
CY2023Q1 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
2631000 usd
CY2024Q2 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
360423 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
(i) one share of the Company’s common stock, (ii) a warrant to purchase one share of the Company’s common stock exercisable at a purchase price of $18.80 per share, and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC will own a 22% interest in Diagnostics.
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4500000 usd
CY2024Q1 us-gaap Sale Of Stock Consideration Received Per Transaction
SaleOfStockConsiderationReceivedPerTransaction
2250000 usd
us-gaap Direct Operating Costs
DirectOperatingCosts
142000 usd
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
127260 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
18.80
CY2023Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1189000 usd
CY2024Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
359919 usd
CY2023Q1 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
2631000 usd
CY2024Q2 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
360423 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
0 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
608000 usd
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
127260 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
18.80
CY2023Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1189000 usd
CY2024Q2 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
360423 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
0 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
608000 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
0 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
608000 usd

Files In Submission

Name View Source Status
0001493152-24-034902-index-headers.html Edgar Link pending
0001493152-24-034902-index.html Edgar Link pending
0001493152-24-034902.txt Edgar Link pending
0001493152-24-034902-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
shph-20240630.xsd Edgar Link pending
shph-20240630_cal.xml Edgar Link unprocessable
shph-20240630_def.xml Edgar Link unprocessable
shph-20240630_lab.xml Edgar Link unprocessable
shph-20240630_pre.xml Edgar Link unprocessable